ASX CODE: CYP
Cynata Therapeutics reveals more positive pre-clinical cancer trial results
Biotechnology company Cynata Therapeutics (ASX: CYP) has published encouraging results from its ongoing preclinical program using its proprietary Cymerus platform.
The company said it was...
Cynata Therapeutics looks to advance Cymerus stem cell treatment into phase 2 trials
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has said that it has “met all clinical endpoints” in its phase 1 trial...
Cynata study shows positive link between stem cells and cardiac function post-heart attack
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has announced positive efficacy data from a study of its Cymerus mesenchymal stem cells...
Phase 2 bone marrow transplant drug trial on the horizon for Cynata Therapeutics
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) may advance to a phase 2 clinical trial of a new stem cell...
Cynata includes coronary artery disease into existing stem cell therapy research platform
Regenerative medicine company Cynata Therapeutics (ASX: CYP) has partnered up with the University of New South Wales (UNSW) in a bid to develop a...
Cynata Therapeutics receives notice of allowance ahead of patent for stem cell platform
A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a Notice...
Cynata Therapeutics finalises Cymerus patent to treat adverse reactions to cancer immunotherapy
Cynata Therapeutics (ASX: CYP) has wrapped up an IP Australia patent application for therapeutic use of its Cymerus stem cell technology in treating adverse reactions...
Cynata receives key FDA approval to progress GvHD drug candidate
For the second time in as many days, the US Food and Drug Administration (FDA) has granted important permission to an ASX-listed company in...
Cynata unveils promising results in treating graft versus host disease with stem cells
Cynata Therapeutics (ASX: CYP) has unveiled “excellent” data from its “world first” clinical trial using its stem cell product CYP-001 in treating steroid resistant...
Cynata finds synergy with US-based biotech developer
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has signed a Memorandum of Understanding (MoU) with Celularity Inc., a US-based biotech...
Cynata Therapeutics advance to second cohort in stem cell trial
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials of its stem cell...
Cynata Therapeutics enrols first cohort for world first clinical trial
Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has enrolled its first cohort for its “world first” clinical trial of its stem...
